Bimekizumab: the new drug in the biologics armamentarium for psoriasis

Freitas, Egídio; Torres, Tiago

doi:10.7573/dic.2021-4-1

Cited by 7 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are IL-17 inhibitors available for the treatment of moderate-severe plaque psoriasis: two monoclonal antibodies targeting IL-17A (Secukinumab, Ixekizumab), one targeting both IL-17A and IL-17F (Bimekizumab), and one against IL-17 receptors (Brodalumab) [ 31 , 56 ] (Table 2 ) [ 48 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 ]. The importance of a direct treatment target of specific cytokines involved in this pathology cannot be understated, leading not only to an important minimization of the adverse effects of immunosuppressive therapy but also to impressive improvements in HP lesions [ 66 ].…”

Section: ⧉ Immunomodulatory Treatment Of Psoriasismentioning

confidence: 99%

Novel concepts in psoriasis: histopathology and markers related to modern treatment approaches

Mihu

Neag²,

Bocşan³

et al. 2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

Psoriasis is a chronic autoimmune disease affecting over 2% of the worldwide population. From an anatomopathological point of view, psoriasis is characterized by immune cells infiltration, epidermal hyperproliferation, and abnormal keratinocyte differentiation. Understanding the pathogenesis of psoriasis will allow clinicians to manage this complex disease. Under these conditions, the application of effective treatments requires a thorough knowledge of all the pathogenetic mechanisms that lead to psoriasis. Numerous immunopathological pathways play crucial roles in the development of new therapies, such as biological therapies, which have been a breakthrough in psoriasis’s treatment. Pharmacogenetics is an essential factor in the patient’s response to treatment. One important pathway targeted by modern treatments is the interleukin (IL)-23/T-helper (Th)17 axis. Like IL-17 inhibitors, IL-23 blockers are a very effective therapy for this autoimmune disease. It is considered that micro-ribonucleic acids (microRNAs) are the starting point for any autoimmune disease. Studying certain microRNA (miR) involved in the inflammatory pathway in psoriasis can find direct targets to future treatments that can even be more specific than actual biological therapies. As such, miR-210 has proven to be up-regulated in psoriasis, also leading to the up-regulation of the Th1/Th17 axis. On the other hand, miR-187 was found to be down-regulated, influencing the outcome of psoriasis by increasing the proliferation of IL-6 stimulated keratinocytes and consecutively generating epidermal thickening. In this review, we are aiming to do an up-to-date briefing of psoriasis histopathology and pharmacogenetic factors that are considered for the accurate evaluation of treatment response.

show abstract

Section: ⧉ Immunomodulatory Treatment Of Psoriasismentioning

confidence: 99%

Novel concepts in psoriasis: histopathology and markers related to modern treatment approaches

Mihu

Neag²,

Bocşan³

et al. 2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

“… 18 Since September 2020, bimekizumab is being reviewed by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of psoriasis. 19 Bimekizumab is currently not FDA approved but is being studied for psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa as well. 20 , 21 …”

Section: Product Availabilitymentioning

confidence: 99%

Review of bimekizumab in the treatment of psoriasis

Koppu

Singh

Kaur

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Bimekizumab, a selective interleukin (IL) 17 inhibitor, is an emerging systemic treatment for moderate-to-severe psoriasis. Although IL-19, IL-22, and IL-36 are implicated in the pathogenesis of psoriasis, IL-17 drives the activation of these interleukins and the formation of psoriatic plaques. This review assesses the efficacy, safety, and implications of bimekizumab in the treatment of moderate-to-severe psoriasis. A review of literature was conducted using the PubMed repository in March 2022. Articles in English discussing the use of bimekizumab in the treatment of psoriasis were included. One phase II and four phase III trials were included. During clinical trials, bimekizumab was more efficacious, when compared to placebo, ustekinumab, adalimumab, and secukinumab in the treatment of moderate to severe psoriasis. Bimekizumab is a promising, efficacious, and relatively tolerable emerging systemic treatment for moderate-to-severe plaque psoriasis.

show abstract

“…Bimekizumab is a humanized monoclonal immunoglobulin G1 (IgG1) antibody that simultaneously targets IL-17A and IL-17F which shows efficacy in the treatment of psoriatic arthritis (PsA) and moderate-tosevere psoriasis. 27 It has demonstrated superior clinical response in all active comparative trials including adalimumab, secukinumab, and ustekinumab. [27][28][29] In the BE ACTIVE study, a 48-week, randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb trial, 206 participants with PsA were randomized to 1 of 4 bimekizumab treatment arms (16 mg Q4W, 160 mg Q4W, 160 mg Q4W with a 320 mg loading dose [LD], 320 mg Q4W) or placebo.…”

Section: Bimekizumabmentioning

confidence: 99%

“…27 It has demonstrated superior clinical response in all active comparative trials including adalimumab, secukinumab, and ustekinumab. [27][28][29] In the BE ACTIVE study, a 48-week, randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb trial, 206 participants with PsA were randomized to 1 of 4 bimekizumab treatment arms (16 mg Q4W, 160 mg Q4W, 160 mg Q4W with a 320 mg loading dose [LD], 320 mg Q4W) or placebo. 30 The primary endpoint of patients achieving at least a 50% improvement in the American College of Rheumatology response criteria (ACR50) at week 12 was met by all bimekizumab treatment groups, with the 160 mg groups, with and without LD, doing best (41.5%-46.3%).…”

Section: Bimekizumabmentioning

confidence: 99%

Psoriasis medications: The future

Russo

Marushchak

Lebwohl

2021

Dermatological Reviews

View full text Add to dashboard Cite

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of keratinocytes and presenting as sharply demarcated, scaly, erythematous plaques and varying levels of systemic involvement.1-3 The pathogenesis of the disease is multifactorial and includes immunologic, genetic, and environmental factors.3 Increased understanding of the involved immune-mediated inflammatory pathways has led to the development of new targeted therapies.3 This review focuses on the safety and efficacy of novel topical, oral, and injectable therapeutic options for treatment of psoriasis.Objectives: The primary objective of this study is to present safety and efficacy data on current and upcoming topical, oral, and biologic therapies for the treatment of psoriasis.Methods: Review of randomized controlled trials on the efficacy and safety of current and upcoming topical, oral, and biologic therapies via an electronic literature search using PubMed, The Cochrane Library, ClinicalTrials.gov, and data presented at AAD VMX 2021.Results: A total of 15 oral, topical or biologic therapies were included and the latest clinical trial safety and efficacy data was presented for the following therapies:

show abstract

Bimekizumab: the new drug in the biologics armamentarium for psoriasis

Cited by 7 publications

References 22 publications

Novel concepts in psoriasis: histopathology and markers related to modern treatment approaches

Novel concepts in psoriasis: histopathology and markers related to modern treatment approaches

Review of bimekizumab in the treatment of psoriasis

Psoriasis medications: The future

Contact Info

Product

Resources

About